PRKD1 and neoplasm: As shown in Fig. 6H, treatment with SD-208 significantly suppressed PKD2 activity in treated- vs. untreated-tumors, suggesting that SD-208 has reached the intended target and the inhibition of PKD may account for growth reduction of tumor xenografts.